Crinetics Pharmaceuticals (CRNX) Total Non-Current Liabilities (2017 - 2026)

Crinetics Pharmaceuticals' Total Non-Current Liabilities history runs 6 years deep, the most recent figure standing at $115.8 million for Q1 2026.

• In Q1 2026, Total Non-Current Liabilities rose 9.65% year-over-year to $115.8 million; the TTM figure through Mar 2026 stood at $115.8 million (up 9.65% YoY), while the FY2025 annual figure was $130.9 million, up 20.17% from the prior year.
• Total Non-Current Liabilities for Q1 2026 stood at $115.8 million, down from $130.9 million in the prior quarter.
• The five-year high for Total Non-Current Liabilities was $130.9 million in Q4 2025, with the low at $96.2 million in Q4 2023.
• The 4-year median for Total Non-Current Liabilities is $109.0 million (2024), against an average of $111.4 million.
• The sharpest annual moves came in 2025 and 2026: Total Non-Current Liabilities gained 20.17% in 2025, then advanced 9.65% in 2026.
• Crinetics Pharmaceuticals' Total Non-Current Liabilities stood at $96.2 million in 2023, then advanced by 13.21% to $109.0 million in 2024, then advanced by 20.17% to $130.9 million in 2025, then decreased by 11.6% to $115.8 million in 2026.
• Business Quant data shows CRNX's Total Non-Current Liabilities at $115.8 million in Q1 2026, $130.9 million in Q4 2025, and $121.0 million in Q3 2025.